DOW — Dow
TL;DR
Dow is a large-cap commodity chemicals company heavily exposed to olefins and polyolefins (polyethylene, polypropylene). The Iran conflict has driven a sharp spike in petchem prices that lifted DOW’s YTD share price ~60–80% and generated material cash tailwinds — but BofA rates the stock Underperform at 35 PO, arguing current prices imply ~1.7 years of peak earnings that are unlikely to persist. The stock looks most extended of the three petchem names; watch for H2 2026 pricing normalization.1
Business
Dow produces commodity and performance chemicals across three segments: Packaging & Specialty Plastics (polyethylene, ethylene), Industrial Intermediates & Infrastructure (polyurethanes, industrial solutions), and Performance Materials & Coatings. Revenue is highly sensitive to ethylene and PE price spreads over feedstock costs (natural gas and naphtha). North American production benefits structurally from cheap US NGL feedstocks.1
Thesis
- Tailwind is temporary, not structural. The Iran conflict disrupted Middle East petchem flows and sent PE prices up ~+35cpp (BofA estimate); BofA models this unwinds through H2 2026 and further in 2027 as trade patterns re-normalize.1
- Oversupply is the base case post-conflict. Global PE utilization was already in the high-60s to low-70s% entering the disruption (vs. ~88% pre-COVID). Chinese capacity additions are massive; ~2mn tonnes of closures would be needed to structurally tighten the market — BofA sees that as unlikely.1
- Earnings peak in 2026, then step down. BofA’s FY26 EBITDA of 5,355mn. Normalized earnings used for valuation are 2027–2028, not 2026.1
- Stock prices in 1.7 years of overearning. BofA calculates excess market cap vs. excess EBITDA implies ~6.8 quarters of peak earnings priced in — the longest duration of the three petchem names covered.1
- Cost initiatives provide partial 2027–2028 cushion. ~$1bn in cumulative cost cuts modeled over 2026–2028 softens but does not offset the commodity pricing headwind.1
Risks
- Upside: Faster-than-expected conflict resolution + rapid PMI rebound shifts sentiment back to normalized earnings; plastics demand surprises to the upside; weaker USD boosts export competitiveness; new product growth in performance materials.1
- Downside: New competitive capacity additions (particularly China) compound oversupply; stagflation weighs on downstream demand; higher US energy/NGL costs compress margins; conflict lingers and asset rationalization remains minimal, leaving no structural tightening.1
Recent catalysts
- 2026-04-06 — BofA downgrades DOW to Underperform from Neutral; raises PO to 31; raises FY26 EBITDA to 823mn. Downgrade driven by extended YTD rally, unsustainable conflict-era tailwinds, and unfavorable 2027+ risk-reward.1
Second-order reads
- 2026-04-06 — BofA US Chemicals note — Iran conflict drove ~+106% rise in NEA ethylene prices since conflict start; petchem prices up broadly across global chains. Implication for DOW: near-term earnings beat likely in 1Q26, but pricing peak expected mid-2026 before normalization.1
Valuation & positioning
| Metric | Value |
|---|---|
| Price (2026-04-05) | $41.00 |
| BofA Price Objective | $35 |
| Rating | Underperform |
| BofA valuation basis | 6.5x FY26E EV/EBITDA |
| FY26E EBITDA | $5,973mn |
| FY27E EBITDA | $5,355mn |
| FY28E EBITDA | $5,788mn |
| FY26E EPS | $2.02 |
| FY27E EPS | $1.43 |
| FY28E EPS | $1.87 |
| Mkt cap | ~$29,528mn |
| Excess mkt cap / excess EBITDA | 6.8 quarters |
| Implied overearning duration | ~1.7 years |
The 6.5x multiple reflects a discount to the historical ~9x framework, with BofA treating 2026 earnings as partially “peak” and anchoring to a more normalized 6.5x on 2027 estimates.1